Prelude Therapeutics Incorporated (PRLD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
200 Powder Mill Road
Wilmington, DE 19803
United States of America (the)
Phone
302 467 1280
Website
Sector
Healthcare
Industry
Biotechnology
Employees
131
First IPO Date
September 25, 2020
| Name | Title | Pay | Year Born |
| Krishna Vaddi | Founder, Chief Executive Officer & Director | 935,256 | 1966 |
| Andrew Combs | Executive Vice President & Chief Chemistry Officer | 562,461 | 1967 |
| Peggy A. Scherle | Chief Scientific Officer | 674,206 | 1962 |
| Bryant David Lim | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | 681,050 | 1971 |
| Naveen Babbar | Senior Vice President of Translation Medicine | 0 | N/A |
| Robert A. Doody Jr. | Senior Vice President of Investor Relations | 0 | N/A |
| Charles Q. Morris MRCP | Chief Medical Officer | 0 | 1965 |
| Sri Sahasranaman | Senior Vice President of Clinical Pharmacology | 0 | N/A |
| Sean Brusky | Chief Business Officer | 0 | 1978 |
| Aimee Crombie | Senior Vice President and Head of Strategic Planning & Operations | 0 | N/A |
| Michele Porreca | Chief People Officer | 0 | N/A |
| Madhu Pudipeddi | Senior Vice President of Technical Operations | 0 | N/A |
| Wan-Jen Hong | Senior Vice President of Clinical Development | 0 | 1979 |
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.